3D high-frequency cardiac MRE detected significantly higher myocardial stiffness in patients with cardiac amyloidosis compared to normal controls (median 11.4 vs 8.2 kPa, P=0.0008).
Observational (n=38)
Can 3D high-frequency cardiac MRE detect increased myocardial stiffness in patients with cardiac amyloidosis compared to healthy controls?
3D high-frequency cardiac MRE is a feasible, contrast-free imaging technique that can quantitatively detect elevated myocardial stiffness in patients with cardiac amyloidosis.
Absolute Event Rate: 11.4% vs 8.2%
p-value: p=0.0008
PURPOSE: To evaluate if cardiac magnetic resonance elastography (MRE) can measure increased stiffness in patients with cardiac amyloidosis. Myocardial tissue stiffness plays an important role in cardiac function. A noninvasive quantitative imaging technique capable of measuring myocardial stiffness could aid in disease diagnosis, therapy monitoring, and disease prognostic strategies. We recently developed a high-frequency cardiac MRE technique capable of making noninvasive stiffness measurements. MATERIALS AND METHODS: In all, 16 volunteers and 22 patients with cardiac amyloidosis were enrolled in this study after Institutional Review Board approval and obtaining formal written consent. All subjects were imaged head-first in the supine position in a 1.5T closed-bore MR imager. 3D MRE was performed using 5 mm isotropic resolution oblique short-axis slices and a vibration frequency of 140 Hz to obtain global quantitative in vivo left ventricular stiffness measurements. The median stiffness was compared between the two cohorts. An octahedral shear strain signal-to-noise ratio (OSS-SNR) threshold of 1.17 was used to exclude exams with insufficient motion amplitude. RESULTS: Five volunteers and six patients had to be excluded from the study because they fell below the 1.17 OSS-SNR threshold. The myocardial stiffness of cardiac amyloid patients (median: 11.4 kPa, min: 9.2, max: 15.7) was significantly higher (P = 0.0008) than normal controls (median: 8.2 kPa, min: 7.2, max: 11.8). CONCLUSION: This study demonstrates the feasibility of 3D high-frequency cardiac MRE as a contrast-agent-free diagnostic imaging technique for cardiac amyloidosis. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017;46:1361-1367.
Arani et al. (Sat,) conducted a observational in Cardiac amyloidosis (n=38). 3D high-frequency cardiac magnetic resonance elastography (MRE) vs. Normal controls was evaluated on Myocardial stiffness (median kPa) (p=0.0008). 3D high-frequency cardiac MRE detected significantly higher myocardial stiffness in patients with cardiac amyloidosis compared to normal controls (median 11.4 vs 8.2 kPa, P=0.0008).